Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guanazodine is a synthetic small molecule belonging to the class of guanidines. Its IUPAC name is N‑[(azocan‑2‑yl)methyl]guanidine, and it has a molecular formula of C9H20N4. Guanazodine has been investigated as an antihypertensive agent, with its primary mechanism believed to involve inhibition of sympathetic nervous system activity through adrenergic neuron blockade. It reached up to phase II clinical trials for at least one investigational indication but does not appear to be approved or widely marketed as a pharmaceutical product[6][8]. Brand names include Sanegit and Sanegyt.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guanazodine.